A Phase 3 interventional study of Tralokinumab and Placebo in Atopic Dermatitis, sponsored by LEO Pharma. Completed at 66 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-11.
Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing tralokinumab in Dermatitis, Atopic — 2 open to participants now, 2 under way, 1 of them phase 3. tralokinumab · Dermatitis, Atopic.
Among the 16 studies testing tralokinumab in Dermatitis, Atopic, this one is the 4th largest by enrollment, is one of 6 that started in 2018, is one of 10 in phase 3, and was the 3rd registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 16 studies testing tralokinumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:
LEO Pharma · Sites in United States, Belgium, Canada and 10 more countries
Ages 6 mo–11 yrs
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
tralokinumab: first FDA approval 2021 (ADBRY), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 380 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 205 across the 16 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 4 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
36 studies in Dermatitis, Atopic by LEO Pharma: 1 open now, 1 under way, 1 of them phase 3. Of 34 finished, 15 (44%) have results posted.
Among the 36 studies in Dermatitis, Atopic by LEO Pharma, this one is the 4th largest by enrollment of the 34 interventional ones that give a count, is one of 8 that started in 2018, is one of 10 in phase 3, and was the 18th registered.
LEO Pharma’s Dermatitis, Atopic studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing tralokinumab in Dermatitis, Atopic, from their registry updates:
Among LEO Pharma’s 36 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
Primary objective:
To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD).
Secondary objectives:
To evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of AD, itch, and health-related quality of life compared with placebo in combination with TCS.
To assess the safety of tralokinumab in combination with TCS when used to treat moderate-to-severe AD for 32 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Week 0 to 16 (initial period): Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A. Week 16 to 32 (continuation period): Tralokinumab continuation SC injection regimen A.
Drug: Tralokinumab
Week 0 to 16 (initial period): Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A. Week 16 to 32 (continuation period): Tralokinumab continuation SC injection regimen B.
Drug: Tralokinumab
Week 0 to 16 (initial period): Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A. Week 16 to 32 (continuation period): Tralokinumab continuation SC injection regimen A.
Drug: Tralokinumab
Week 0 to 16 (initial period): Placebo loading SC injection on Day 0 followed by placebo injection regimen A. Week 16 to 32 (continuation period): Tralokinumab continuation SC injection regimen A.
Drug: Tralokinumab · Drug: Placebo
Week 0 to 16 (initial period): Placebo loading SC injection on Day 0 followed by placebo injection regimen A. Week 16 to 32 (continuation period): Placebo continuation SC injection regimen A.
Drug: Placebo
Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16
IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 (clear) to 4 (severe).
Time frame: Week 16
Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 16
EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.
Time frame: Week 16
Reduction of Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average) of at Least 4 From Baseline to Week 16
Worst Daily Pruritus NRS is used by the participant to evaluate their worst itch severity over the past 24 hours. The score ranges from 0 ('no itch') to 10 ('worst itch imaginable') on an 11-point scale.
Time frame: Week 0 to Week 16
Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16
SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.
Time frame: Week 0 to Week 16
Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16
DLQI is used by the participant to evaluate the impact of their condition on 10 different aspects of health-related quality of life (HRQoL) over the last week. Each item is scored on a 4-point Likert scale ranging from 0 (not at all/not relevant) to 3 (very much). The total score which is the sum of the 10 items ranges from 0 to 30, with a higher score indicating a poorer HRQoL.
Time frame: Week 0 to Week 16
Frequency of Anti-drug Antibodies (ADA)
Presence of ADA from Week 0 to Week 32 was measured. Data were reported in the following categories: positive (presence of ADA at baseline and/or presence of ADA at at least 1 post-baseline assessment), perishing (presence of ADA at baseline and absence of ADA at all post-baseline assessments), negative (absence of ADA at all assessments), no post-baseline ADA assessment. Perishing ADAs were not assessed in the continuation treatment period.
Time frame: Week 0 to Week 16, Week 16 to Week 32
Amount of Topical Corticosteroid (TCS) Used Through Week 16 Assuming no TCS Used From the Non-returned Tubes
Assessed as the amount of TCS weighed from previous visits, assuming no TCS was used from the non-returned tubes. Measurements were collected as TCS weight (g) between the visits.
Time frame: Week 1-2 to Week 15-16
Amount of Topical Corticosteroid (TCS) Used Through Week 16 Assuming All TCS Used From the Non-returned Tubes
Assessed as the amount of TCS weighed from previous visits, assuming all TCS was used from the non-returned tubes. Measurements were collected as TCS weight (g) between the visits.
Time frame: Week 1-2 to Week 15-16
Number of Atopic Dermatitis Flares Through Week 16
Assessed as appearance of new flares since previous visit.
Time frame: Week 0 to Week 16
Number of Days Without Topical Treatment Use From Baseline to Week 16
Participants assessed their use of topical treatment over the past 24 hours using a response scale ('yes', 'no'). Measurements of number of days per week were used in the analysis.
Time frame: Week 1 to Week 16
Participants Achieving at Least 50% Reduction in Eczema Area and Severity Index (EASI) at Week 16
EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.
Time frame: Week 16
Participants Achieving at Least 90% Reduction in Eczema Area and Severity Index (EASI) at Week 16
EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.
Time frame: Week 16
Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score
EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.
Time frame: Week 0 to Week 16
Participants Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16
SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.
Time frame: Week 16
Participants Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16
SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.
Time frame: Week 16
Change From Baseline to Week 16 in Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average)
Worst Daily Pruritus NRS is used by the participant to evaluate their worst itch severity over the past 24 hours. The score ranges from 0 ('no itch') to 10 ('worst itch imaginable') on an 11-point scale.
Time frame: Week 0 to Week 16
Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of at Least 4 Points Among Participants With Baseline DLQI ≥4
DLQI is used by the participant to evaluate the impact of their condition on 10 different aspects of health-related quality of life (HRQoL) over the last week. Each item is scored on a 4-point Likert scale ranging from 0 (not at all/not relevant) to 3 (very much). The total score which is the sum of the 10 items ranges from 0 to 30, with a higher score indicating a poorer HRQoL.
Time frame: Week 0 to Week 16
Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 32 Among Participants With IGA Score of 0 or 1 at Week 16 After Initial Randomisation to Tralokinumab
IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 (clear) to 4 (severe).
Time frame: Week 32
Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 32 Among Participants Who Had Achieved at Least 75% Reduction in EASI at Week 16 After Initial Randomisation to Tralokinumab
EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.
Time frame: Week 32
| Milestone | Tralokinumab Q2W+TCS | Placebo+TCS | Tralokinumab R/Q2W+TCS | Tralokinumab R/Q4W+TCS | Tralokinumab NR/Q2W+TCS | Placebo NR/Tralokinumab Q2W+TCS | Placebo R/Placebo+TCS | Safety Follow-up |
|---|---|---|---|---|---|---|---|---|
| Started | 253 | 127 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 235 | 120 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 18 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Tralokinumab Q2W+TCS | Placebo+TCS | Tralokinumab R/Q2W+TCS | Tralokinumab R/Q4W+TCS | Tralokinumab NR/Q2W+TCS | Placebo NR/Tralokinumab Q2W+TCS | Placebo R/Placebo+TCS | Safety Follow-up |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 69 | 69 | 95 | 79 | 41 | 0 |
| Completed | 0 | 0 | 68 | 65 | 87 | 72 | 38 | 0 |
| Not completed | 0 | 0 | 1 | 4 | 8 | 7 | 3 | 0 |
| Milestone | Tralokinumab Q2W+TCS | Placebo+TCS | Tralokinumab R/Q2W+TCS | Tralokinumab R/Q4W+TCS | Tralokinumab NR/Q2W+TCS | Placebo NR/Tralokinumab Q2W+TCS | Placebo R/Placebo+TCS | Safety Follow-up |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 278 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 62 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 216 |
IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 (clear) to 4 (severe).
| Participants | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 | 98 | 33 |
EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.
| Participants | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 16 | 141 | 45 |
Worst Daily Pruritus NRS is used by the participant to evaluate their worst itch severity over the past 24 hours. The score ranges from 0 ('no itch') to 10 ('worst itch imaginable') on an 11-point scale.
| Participants | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Reduction of Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average) of at Least 4 From Baseline to Week 16 | 113 | 43 |
SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.
| units on a scale | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16 | -37.7 ± 1.25 | -26.8 ± 1.80 |
DLQI is used by the participant to evaluate the impact of their condition on 10 different aspects of health-related quality of life (HRQoL) over the last week. Each item is scored on a 4-point Likert scale ranging from 0 (not at all/not relevant) to 3 (very much). The total score which is the sum of the 10 items ranges from 0 to 30, with a higher score indicating a poorer HRQoL.
| units on a scale | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16 | -11.7 ± 0.39 | -8.8 ± 0.56 |
Presence of ADA from Week 0 to Week 32 was measured. Data were reported in the following categories: positive (presence of ADA at baseline and/or presence of ADA at at least 1 post-baseline assessment), perishing (presence of ADA at baseline and absence of ADA at all post-baseline assessments), negative (absence of ADA at all assessments), no post-baseline ADA assessment. Perishing ADAs were not assessed in the continuation treatment period.
| Participants | Initial Treatment Period - Tralokinumab Q2W+TCS | Initial Treatment Period - Placebo+TCS | Continuation Treatment Period - Tralokinumab R/Q2W+TCS | Continuation Treatment Period - Tralokinumab R/Q4W+TCS | Continuation Treatment Period - Tralokinumab NR/Q2W+TCS | Continuation Treatment Period - Placebo NR/Tralokinumab Q2W+TCS | Continuation Treatment Period - Placebo R/Placebo+TCS |
|---|---|---|---|---|---|---|---|
| Initial treatment period (Week 0 to Week 16) — Positive | 2 | 3 | 0 | 0 | 0 | 0 | 0 |
| Initial treatment period (Week 0 to Week 16) — Perishing | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Initial treatment period (Week 0 to Week 16) — Negative | 246 | 123 | 0 | 0 | 0 | 0 | 0 |
| Initial treatment period (Week 0 to Week 16) — No post-baseline ADA assessment | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Continuation treatment period (Week 16 to Week 32) — Positive | 0 | 0 | 0 | 2 | 0 | 3 | 2 |
| Continuation treatment period (Week 16 to Week 32) — Perishing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Continuation treatment period (Week 16 to Week 32) — Negative | 0 | 0 | 66 | 63 | 92 | 74 | 37 |
| Continuation treatment period (Week 16 to Week 32) — No post-baseline ADA assessment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Assessed as the amount of TCS weighed from previous visits, assuming no TCS was used from the non-returned tubes. Measurements were collected as TCS weight (g) between the visits.
| g | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Week 1-2 | 29.3 ± 2.45 | 32.8 ± 3.47 |
| Week 3-4 | 19.7 ± 1.86 | 26.6 ± 2.66 |
| Week 5-6 | 18.5 ± 1.72 | 23.2 ± 2.46 |
| Week 7-8 | 17.0 ± 2.04 | 24.3 ± 2.93 |
| Week 9-10 | 14.8 ± 1.66 | 23.9 ± 2.38 |
| Week 11-12 | 11.6 ± 1.38 | 19.6 ± 2.00 |
| Week 13-14 | 12.7 ± 1.61 | 23.0 ± 2.33 |
| Week 15-16 | 11.6 ± 1.57 | 20.2 ± 2.27 |
Assessed as the amount of TCS weighed from previous visits, assuming all TCS was used from the non-returned tubes. Measurements were collected as TCS weight (g) between the visits.
| g | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Week 1-2 | 40.1 ± 3.22 | 40.1 ± 4.57 |
| Week 3-4 | 32.4 ± 3.00 | 31.3 ± 4.27 |
| Week 5-6 | 29.2 ± 2.89 | 30.6 ± 4.13 |
| Week 7-8 | 25.2 ± 2.89 | 30.0 ± 4.15 |
| Week 9-10 | 22.5 ± 2.61 | 26.9 ± 3.76 |
| Week 11-12 | 16.9 ± 2.23 | 23.1 ± 3.22 |
| Week 13-14 | 16.6 ± 2.22 | 25.5 ± 3.23 |
| Week 15-16 | 15.3 ± 2.26 | 24.8 ± 3.27 |
Assessed as appearance of new flares since previous visit.
| number of flares | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Number of Atopic Dermatitis Flares Through Week 16 | 119 | 75 |
Participants assessed their use of topical treatment over the past 24 hours using a response scale ('yes', 'no'). Measurements of number of days per week were used in the analysis.
| days | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Week 1 | 2.6 ± 0.17 | 2.5 ± 0.25 |
| Week 2 | 3.0 ± 0.18 | 2.6 ± 0.27 |
| Week 3 | 2.9 ± 0.17 | 2.7 ± 0.25 |
| Week 4 | 3.1 ± 0.17 | 2.7 ± 0.25 |
| Week 5 | 3.2 ± 0.17 | 2.7 ± 0.25 |
| Week 6 | 3.1 ± 0.18 | 2.8 ± 0.26 |
| Week 7 | 3.3 ± 0.17 | 2.7 ± 0.25 |
| Week 8 | 3.3 ± 0.18 | 3.0 ± 0.26 |
| Week 9 | 3.6 ± 0.17 | 2.6 ± 0.25 |
| Week 10 | 3.4 ± 0.17 | 2.7 ± 0.25 |
| Week 11 | 3.6 ± 0.18 | 2.7 ± 0.26 |
| Week 12 | 3.4 ± 0.18 | 2.7 ± 0.26 |
| Week 13 | 3.5 ± 0.18 | 2.7 ± 0.26 |
| Week 14 | 3.3 ± 0.18 | 2.6 ± 0.26 |
| Week 15 | 3.5 ± 0.18 | 2.8 ± 0.26 |
| Week 16 | 3.4 ± 0.19 | 3.0 ± 0.27 |
EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.
| Participants | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Participants Achieving at Least 50% Reduction in Eczema Area and Severity Index (EASI) at Week 16 | 200 | 73 |
EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.
| Participants | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Participants Achieving at Least 90% Reduction in Eczema Area and Severity Index (EASI) at Week 16 | 83 | 27 |
EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.
| units on a scale | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score | -21.0 ± 0.67 | -15.6 ± 0.96 |
SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.
| Participants | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Participants Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16 | 154 | 48 |
SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.
| Participants | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Participants Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16 | 60 | 16 |
Worst Daily Pruritus NRS is used by the participant to evaluate their worst itch severity over the past 24 hours. The score ranges from 0 ('no itch') to 10 ('worst itch imaginable') on an 11-point scale.
| units on a scale | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Change From Baseline to Week 16 in Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average) | -4.1 ± 0.15 | -2.9 ± 0.21 |
DLQI is used by the participant to evaluate the impact of their condition on 10 different aspects of health-related quality of life (HRQoL) over the last week. Each item is scored on a 4-point Likert scale ranging from 0 (not at all/not relevant) to 3 (very much). The total score which is the sum of the 10 items ranges from 0 to 30, with a higher score indicating a poorer HRQoL.
| Participants | Tralokinumab Q2W+TCS | Placebo+TCS |
|---|---|---|
| Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of at Least 4 Points Among Participants With Baseline DLQI ≥4 | 207 | 81 |
IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 (clear) to 4 (severe).
| Participants | Tralokinumab R/Q2W+TCS | Tralokinumab R/Q4W+TCS |
|---|---|---|
| Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 32 Among Participants With IGA Score of 0 or 1 at Week 16 After Initial Randomisation to Tralokinumab | 43 | 38 |
EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.
| Participants | Tralokinumab R/Q2W+TCS | Tralokinumab R/Q4W+TCS |
|---|---|---|
| Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 32 Among Participants Who Had Achieved at Least 75% Reduction in EASI at Week 16 After Initial Randomisation to Tralokinumab | 62 | 59 |
Collected over Initial treatment period (Week 0 to Week 16), continuation treatment period (Week 16 to Week 32), safety follow-up (Week 32 to Week 46).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Initial Treatment Period: Tralokinumab Q2W+TCS | 0/252 (0%) | 2/252 (0.8%) | 118/252 (46.8%) |
| Initial Treatment Period: Placebo+TCS | 0/126 (0%) | 4/126 (3.2%) | 36/126 (28.6%) |
| Continuation Treatment Period: Tralokinumab R/Q2W+TCS | 0/69 (0%) | 3/69 (4.3%) | 30/69 (43.5%) |
| Continuation Treatment Period: Tralokinumab R/Q4W+TCS | 0/69 (0%) | 0/69 (0%) | 24/69 (34.8%) |
| Continuation Treatment Period: Tralokinumab NR/Q2W+TCS | 0/95 (0%) | 2/95 (2.1%) | 41/95 (43.2%) |
| Continuation Treatment Period: Placebo NR/Tralokinumab Q2W+TCS | 0/79 (0%) | 0/79 (0%) | 32/79 (40.5%) |
| Continuation Treatment Period: Placebo R/Placebo+TCS | 0/41 (0%) | 1/41 (2.4%) | 12/41 (29.3%) |
| Safety Follow-up | 0/278 (0%) | 3/278 (1.1%) | 10/278 (3.6%) |
| Event | Initial Treatment Period: Tralokinumab Q2W+TCS | Initial Treatment Period: Placebo+TCS | Continuation Treatment Period: Tralokinumab R/Q2W+TCS | Continuation Treatment Period: Tralokinumab R/Q4W+TCS | Continuation Treatment Period: Tralokinumab NR/Q2W+TCS | Continuation Treatment Period: Placebo NR/Tralokinumab Q2W+TCS | Continuation Treatment Period: Placebo R/Placebo+TCS | Safety Follow-up |
|---|---|---|---|---|---|---|---|---|
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/252 | 0/126 | 0/69 | 0/69 | 0/95 | 0/79 | 1/41 | 0/278 |
| AppendicitisInfections and infestations | 0/252 | 0/126 | 1/69 | 0/69 | 0/95 | 0/79 | 0/41 | 0/278 |
| Gastroenteritis clostridialInfections and infestations | 0/252 | 0/126 | 1/69 | 0/69 | 0/95 | 0/79 | 0/41 | 0/278 |
| Ligament ruptureInjury, poisoning and procedural complications | 0/252 | 0/126 | 1/69 | 0/69 | 0/95 | 0/79 | 0/41 | 0/278 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/252 | 0/126 | 1/69 | 0/69 | 0/95 | 0/79 | 0/41 | 0/278 |
| Wrist fractureInjury, poisoning and procedural complications | 0/252 | 0/126 | 0/69 | 0/69 | 1/95 | 0/79 | 0/41 | 0/278 |
| DepressionPsychiatric disorders | 0/252 | 0/126 | 0/69 | 0/69 | 1/95 | 0/79 | 0/41 | 0/278 |
| Dermatitis infectedInfections and infestations | 0/252 | 1/126 | 0/69 | 0/69 | 0/95 | 0/79 | 0/41 | 0/278 |
| Herpes zosterInfections and infestations | 0/252 | 1/126 | 0/69 | 0/69 | 0/95 | 0/79 | 0/41 | 0/278 |
| Meningitis asepticInfections and infestations | 0/252 | 1/126 | 0/69 | 0/69 | 0/95 | 0/79 | 0/41 | 0/278 |
| Event | Initial Treatment Period: Tralokinumab Q2W+TCS | Initial Treatment Period: Placebo+TCS | Continuation Treatment Period: Tralokinumab R/Q2W+TCS | Continuation Treatment Period: Tralokinumab R/Q4W+TCS | Continuation Treatment Period: Tralokinumab NR/Q2W+TCS | Continuation Treatment Period: Placebo NR/Tralokinumab Q2W+TCS | Continuation Treatment Period: Placebo R/Placebo+TCS | Safety Follow-up |
|---|---|---|---|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 49/252 | 14/126 | 12/69 | 9/69 | 20/95 | 15/79 | 7/41 | 0/278 |
| ConjunctivitisInfections and infestations | 28/252 | 4/126 | 4/69 | 0/69 | 3/95 | 3/79 | 1/41 | 0/278 |
| Upper respiratory tract infectionInfections and infestations | 19/252 | 6/126 | 7/69 | 3/69 | 6/95 | 3/79 | 2/41 | 2/278 |
| HeadacheNervous system disorders | 22/252 | 6/126 | 2/69 | 5/69 | 7/95 | 2/79 | 1/41 | 3/278 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 6/252 | 10/126 | 1/69 | 1/69 | 8/95 | 6/79 | 2/41 | 2/278 |
| Injection site reactionGeneral disorders | 17/252 | 0/126 | 5/69 | 4/69 | 5/95 | 2/79 | 0/41 | 0/278 |
| DiarrhoeaGastrointestinal disorders | 8/252 | 2/126 | 4/69 | 1/69 | 1/95 | 2/79 | 2/41 | 1/278 |
| NauseaGastrointestinal disorders | 0/252 | 1/126 | 3/69 | 4/69 | 3/95 | 1/79 | 0/41 | 2/278 |
| Oral herpesInfections and infestations | 4/252 | 1/126 | 3/69 | 4/69 | 4/95 | 2/79 | 1/41 | 0/278 |
| Age, Categorical(Participants) | Tralokinumab Q2W+TCS | Placebo+TCS | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 237 | 119 | 356 |
| >=65 years | 16 | 8 | 24 |
| Age, Continuous(years) | Tralokinumab Q2W+TCS | Placebo+TCS | Total |
|---|---|---|---|
| Mean | 39.8 ± 15.3 | 37.7 ± 14.8 | 39.1 ± 15.2 |
| Sex: Female, Male(Participants) | Tralokinumab Q2W+TCS | Placebo+TCS | Total |
|---|---|---|---|
| Female | 128 | 43 | 171 |
| Male | 125 | 84 | 209 |
| Race/Ethnicity, Customized(Participants) | Tralokinumab Q2W+TCS | Placebo+TCS | Total |
|---|---|---|---|
| Race — White | 203 | 85 | 288 |
| Race — Black or African American | 23 | 12 | 35 |
| Race — Asian | 17 | 24 | 41 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Race — Other | 9 | 5 | 14 |
| Race — Hispanic or Latino | 0 | 0 | 0 |
| Race — Not Hispanic or Latino | 0 | 0 | 0 |
| Ethnicity — White | 0 | 0 | 0 |
| Ethnicity — Black or African American | 0 | 0 | 0 |
| Ethnicity — Asian | 0 | 0 | 0 |
| Ethnicity — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Ethnicity — Other | 0 | 0 | 0 |
| Ethnicity — Hispanic or Latino | 25 | 9 | 34 |
| Ethnicity — Not Hispanic or Latino | 228 | 118 | 346 |
| Region of Enrollment(Participants) | Tralokinumab Q2W+TCS | Placebo+TCS | Total |
|---|---|---|---|
| Belgium | 15 | 4 | 19 |
| Canada | 34 | 26 | 60 |
| Germany | 42 | 15 | 57 |
| Netherlands | 9 | 7 | 16 |
| Poland | 48 | 19 | 67 |
| Spain | 12 | 15 | 27 |
| United Kingdom | 21 | 13 | 34 |
| United States | 72 | 28 | 100 |
| Age at onset of atopic dermatitis(years) | Tralokinumab Q2W+TCS | Placebo+TCS | Total |
|---|---|---|---|
| Median | 4.0 (1.0 to 18.0) | 2.0 (1.0 to 12.0) | 4.0 (1.0 to 16.0) |
| Duration of atopic dermatitis(years) | Tralokinumab Q2W+TCS | Placebo+TCS | Total |
|---|---|---|---|
| Mean | 28.0 ± 16.5 | 28.7 ± 15.0 | 28.2 ± 16.0 |
| Body surface area with atopic dermatitis(percentage affected) | Tralokinumab Q2W+TCS | Placebo+TCS | Total |
|---|---|---|---|
| Mean | 47.6 ± 23.3 | 49.0 ± 25.9 | 48.1 ± 24.2 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Mar 2019, 12 months.
Results were first posted in Jan 2021, 1 year 10 months after primary completion. A results delay was requested in Oct 2019.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 12 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tralokinumab